Table 1. Demographic and immunologic parameters of persons living with HIV (N = 149).
| Demographic Parameters | |
| Age, years | 51.0 (46.0–57.5) |
| Male, n(%) | 132 (88.6%) |
| Caucasian ethnicity, n(%) | 86 (57.7%) |
| Immunologic Parameters | |
| Undetectable HIV RNA < 50 copies/ml, n(%) | 126 (84.6%) |
| Nadir CD4 T cell count, cells/ μL | 150 (39, 266) |
| CD4 T cell count, cells/μL | 505.0 (345.0–660.5) |
| CD4 T cell % | 29.0% (21.0% - 36.5%) |
| Activated CD8 T cell % (CD8+ HLA-DR CD38+) | 10.5% (7.6% - 17.0%) |
| Negative checkpoint receptors (%) | |
| PD1+ CD4 T cell | 41.1 (30.3–48.3) |
| TIGIT+ CD4 T cell | 22.6 (16.4–28.3) |
| TIM3+ CD4 T cell | 15.7 (11.9–19.2) |
| TIGIT+PD1+ CD4 T cell | 15.8 (11.0–20.9) |
| TIM3+PD1+ CD4 T cell | 6.49 (4.1–9.2) |
| TIGIT+TIM3+ CD4 T cell | 3.5 (2.6–5.2) |
| PD1+ CD8 T cell | 36.3 (25.7–47.3) |
| TIGIT+ CD8 T cell | 44 (36.4–59.4) |
| TIM3+ CD8 T cell | 21.9 (18.1–28.0) |
| TIGIT+PD1+ CD8 T cell | 24.4 (17.7–32.0) |
| TIM3+PD1+ CD8 T cell | 5.36 (3.7–7.7) |
| TIGIT+TIM3+ CD8 T cell | 8.64 (6.1–12.9) |
| Senescent markers (%) | |
| CD57+CD28- CD8 T cell | 17.3 (12.7–24.4) |
| CD57+CD28- CD4 T cell | 4.16 (1.1–9.9) |
| Monocyte subsets (%) | |
| Classical (CD14++CD16−) | 75.9 (70.4–81.9) |
| Intermediate (CD14++CD16+) | 1.6 (0.6–4.2) |
| Non-classical (CD14low/+CD16++) | 6.0 (4.0–9.1) |
| Plasma soluble biomarkers | |
| CRP, ng/mL | 10,886.3 (3,584.0–46,060.0) |
| IFN-γ, pg/mL | 0.7 (0.4–1.3) |
| IL-1β, pg/mL | 0.3 (0.3–0.3) |
| IL-6, pg/mL | 1.6 (0.9–2.5) |
| IL-8, pg/mL | 3.5 (2.7–4.4) |
| IL-10, pg/mL | 2.1 (0.8–5.0) |
| MCP-1, pg/mL | 147.0 (115.0–179.1) |
| MMP-9, ng/mL | 55.4 (37.3–87.0) |
| MPO, ng/mL | 16.4 (11.4–23.0) |
| SAA, ng/mL | 14,000 (3,933.2–46,224.0) |
| SAP, ng/mL | 88,660.3 (51,867.1–181,582.0) |
| sE-selectin, ng/mL | 33.6 (23.1–48.0) |
| sICAM-1, ng/mL | 140.1 (110.0–172.0) |
| sVCAM-1, ng/mL | 1168.5 (931.0–1335.4) |
| TNF-α, pg/mL | 3.1 (1.8–4.5) |
| tPAI-1, ng/mL | 86.1 (68.0–113.4) |
| VEGF, pg/mL | 24.4 (13.4–49.5) |
| Mitochondrial assessments | |
| Complex I, optical density/ug x 103 | 65.5 (48.0–87.0) |
| Complex IV, optical density/ug x 103 | 49.2 (37.3–64.3) |
| Presence of mitochondria-specific 8-Oxo-2'-deoxyguanosine (n, %) break frequency* | 85 (53.1%) |
Values shown are median (quartile 1, quartile 3), unless otherwise specified.
*Patients with available mt-specific 8-oxo-dG (N = 147)